Clinuvel CEO discusses positive phase III results

13 Jul 2010

Dr Philippe Wolgen, CLINUVEL's CEO, discusses the results of the company’s Phase III study of SCENESSE® in erythropoietic protoporphyria (CUV017)

This audio file is available for download in mp3 format. Right click here and select "Save target as" to save this file to your computer.

Quick Links